NEW YORK, March 23, 2021 /PRNewswire/ -- Oppenheimer
& Co. Inc. ("Oppenheimer"), a leading investment bank, wealth
manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY),
today announced the continued build-out of its Healthcare
leadership team within the firm's Investment Banking
business. The Healthcare Investment Banking team has added
Jonathan Fassberg in the newly
created role of Vice Chairman, Brian
Korb as Managing Director, and Don
Ritucci as Managing Director and Head of Healthcare Mergers
and Acquisitions ("M&A").
The addition of these new senior executives reflects
Oppenheimer's continued leadership in aligning M&A, capital
raising and other investment banking services across the healthcare
space, as well as the firm's commitment to continuously enhance its
capabilities in this large and fast-growing sector.
Mr. Fassberg, and Mr. Korb will be based in New York and will report to Michael A. Margolis, R.Ph., Co-Head of
Healthcare Investment Banking. Don
Ritucci, also based in New
York, will report to Robert
Lowenthal, Head of Investment Banking.
Mr. Fassberg said, "I am excited to help drive the next stage of
growth and success for Oppenheimer's Healthcare Investment Banking
group. There has never been a better moment to enhance
Oppenheimer's position as the clear investment bank of choice for
healthcare, biotech, and life sciences firms. The
opportunities emerging in this space have never been greater for
firms like Oppenheimer that have a proven ability to serve
healthcare businesses seeking to expand via M&A and capital
raising transactions that are thoughtfully structured and
As Vice Chairman, Mr. Fassberg will leverage his deep experience
and extensive contacts across the healthcare spectrum – including
biotech and life sciences – and will bring his entrepreneurial
approach to enhance Oppenheimer's presence in the sector. As
Managing Director, Mr. Korb brings extensive knowledge of the life
science sector, relationships with companies as well as
institutional investors that will reinforce the firm's already
formidable capabilities in healthcare investment banking.
Mr. Fassberg and Mr. Korb have worked together for over 20 years
in this sector, starting with The Trout Group, a leading investor
relations firm in life sciences founded by Mr. Fassberg and now
known as Solebury Trout.
Mr. Fassberg comes to Oppenheimer with 30 years of relevant
experience, having worked at DuPont Pharmaceuticals as well as
several boutique investment banks as an equity research analyst
early in his career. Mr. Korb has more than 20 years' life science
experience, largely spent at The Trout Group and Solebury Trout. He
led the M&A efforts of The Trout Group's sale to PNC Bank and
was most recently Co-Head of Life Sciences at Solebury Trout.
Together, they will leverage the full scope of Oppenheimer's
resources — including Investment Banking, Capital Markets, Sales
& Trading, Research, and Wealth Management — to further elevate
Oppenheimer's ability to deliver an exceptional experience for
Boards and management teams of healthcare businesses seeking
M&A advisory and capital raising support.
In addition, Mr. Ritucci, as Head of M&A for Healthcare
Investment Banking, will be responsible for origination and
execution of advisory transactions across all verticals, including
Healthcare Services, Medical Devices, Tools & Diagnostics,
Pharmaceuticals and Biotech. His expertise will further enable
Oppenheimer to meet the rapidly evolving needs of the firm's
growing list of clients.
Mr. Ritucci brings over 28 years of relevant experience,
providing M&A advisory to clients across the healthcare
industry. He has executed numerous sell-side and buy-side
M&A transactions for private equity clients, public companies
and founder-owned businesses. Prior to joining Oppenheimer,
Mr. Ritucci led the middle market M&A effort at
Jefferies. Previously, he headed financial sponsor coverage
and healthcare investment banking at Imperial Capital LLC and was a
Managing Director focusing on healthcare M&A at UBS Investment
31st ANNUAL HEALTHCARE CONFERENCE
Recently, Oppenheimer's 31st Annual Healthcare
Conference provided investors with a broad spectrum of public and
private healthcare companies spanning all major sectors of the
healthcare industry: bio & specialty pharmaceuticals;
biotechnology; medical devices; life science tools and diagnostics;
healthcare information technology and distribution; and healthcare
providers and servicers.
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc.
(Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), and its affiliates provide a
full range of wealth management, securities brokerage and
investment banking services to high-net-worth individuals,
families, corporate executives, local governments, businesses and
institutions. For more information, please visit
Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
firstname.lastname@example.org or email@example.com
SOURCE Oppenheimer & Co. Inc.